Jonathan Horiuchi
Cardiovascular Disease · Flemington, NJNPI 1659338077
Payments from drug & device makers
Across 294 payments — averaging $15.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$893
- Novartis$594
- Amgen$357
- Merck$305
- Boston Scientific$290
- Pfizer$229
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,616100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 69 | $893 |
| Novartis | 43 | $594 |
| Amgen | 25 | $357 |
| Merck | 22 | $305 |
| Boston Scientific | 6 | $290 |
| Pfizer | 13 | $229 |
| Esperion Therapeutics, Inc. | 15 | $214 |
| E.r. Squibb & Sons, L.L.C. | 14 | $208 |
| AstraZeneca | 13 | $182 |
| Atricure, Inc. | 5 | $155 |
| Amarin Pharma, Inc. | 11 | $152 |
| Sanofi-aventis U.S. LLC | 10 | $143 |
| Boehringer Ingelheim | 10 | $124 |
| Abiomed | 1 | $114 |
| Kowa Pharmaceuticals America, Inc. | 8 | $100 |
| Medtronic | 2 | $76 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $63 |
| Regeneron Healthcare Solutions, Inc. | 4 | $59 |
| Philips North America LLC | 2 | $59 |
| Inspire Medical Systems, Inc. | 2 | $56 |
| Daiichi Sankyo Inc. | 3 | $46 |
| Arbor Pharmaceuticals, Inc. | 3 | $40 |
| Gilead | 3 | $36 |
| Abbott | 1 | $25 |
| Altathera Pharmaceuticals LLC | 1 | $20 |
| Edwards Lifesciences | 1 | $18 |
| United Therapeutics Corporation | 1 | $17 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Baxter Healthcare | 1 | $14 |
| Lundbeck LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,616 in reported general payments places this provider in the 60th percentile of 1,006 cardiovascular disease providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 275 | $283,452 |
| XareltoRivaroxaban | 45 | $61,100 |
| EntrestoSacubitril/Valsartan | 16 | $27,214 |
| Repatha SureclickEvolocumab | 14 | $17,527 |
| Ezetimibe | 121 | $6,581 |
| Metoprolol Succinate | 316 | $5,252 |
| Candesartan Cilexetil | 18 | $2,619 |
| Atorvastatin Calcium | 270 | $2,495 |
| Ranolazine ErRanolazine | 29 | $2,369 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 31 | $1,548 |
| Carvedilol | 137 | $1,474 |
| Flecainide Acetate | 32 | $1,438 |
| Rosuvastatin Calcium | 103 | $1,336 |
| Olmesartan Medoxomil | 43 | $1,299 |
| Amlodipine Besylate | 140 | $1,039 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $229 | $283,452275 claims |
| Johnson & JohnsonXarelto | $893 | $61,10045 claims |
| NovartisEntresto | $594 | $27,21416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Flemington
- Andrey EspinozaFlemington$571K
- Austin KutscherFlemington$117K
- Glen TonnessenFlemington$90K
- Robert KippermanMorristown$5.3M
- Sharan MahalBridgewater$3.5M
- Linda GillamMorristown$2.2M
- Mark GelerntHaddon Heights$2M
- Robert FishbergSpringfield$1.9M
- Dilip ViswanathHaddon Heights$1.8M
- Marc CohenNewark$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.